229 related articles for article (PubMed ID: 28039837)
21. Free-energy-based methods for binding profile determination in a congeneric series of CDK2 inhibitors.
Fidelak J; Juraszek J; Branduardi D; Bianciotto M; Gervasio FL
J Phys Chem B; 2010 Jul; 114(29):9516-24. PubMed ID: 20593892
[TBL] [Abstract][Full Text] [Related]
22. Molecular dynamics and QM/MM-based 3D interaction analyses of cyclin-E inhibitors.
Pasha FA; Neaz MM
J Mol Model; 2013 Feb; 19(2):879-91. PubMed ID: 23086460
[TBL] [Abstract][Full Text] [Related]
23. Pyrimidine-based pyrazoles as cyclin-dependent kinase 2 inhibitors: Design, synthesis, and biological evaluation.
Vekariya MK; Vekariya RH; Brahmkshatriya PS; Shah NK
Chem Biol Drug Des; 2018 Sep; 92(3):1683-1691. PubMed ID: 29767460
[TBL] [Abstract][Full Text] [Related]
24. Analysis of CDK2 active-site hydration: a method to design new inhibitors.
Kríz Z; Otyepka M; Bártová I; Koca J
Proteins; 2004 May; 55(2):258-74. PubMed ID: 15048820
[TBL] [Abstract][Full Text] [Related]
25. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors.
Tripathi SK; Muttineni R; Singh SK
J Theor Biol; 2013 Oct; 334():87-100. PubMed ID: 23727278
[TBL] [Abstract][Full Text] [Related]
26. A computational study of the protein-ligand interactions in CDK2 inhibitors: using quantum mechanics/molecular mechanics interaction energy as a predictor of the biological activity.
Alzate-Morales JH; Contreras R; Soriano A; Tuñon I; Silla E
Biophys J; 2007 Jan; 92(2):430-9. PubMed ID: 17085505
[TBL] [Abstract][Full Text] [Related]
27. Comparative analysis of various electrostatic potentials on docking precision against cyclin-dependent kinase 2 protein: a multiple docking approach.
Tripathi SK; Soundarya RN; Singh P; Singh SK
Chem Biol Drug Des; 2015 Feb; 85(2):107-18. PubMed ID: 24923208
[TBL] [Abstract][Full Text] [Related]
28. Molecular modeling studies of 4,5-dihydro-1H-pyrazolo[4,3-h] quinazoline derivatives as potent CDK2/Cyclin a inhibitors using 3D-QSAR and docking.
Ai Y; Wang ST; Sun PH; Song FJ
Int J Mol Sci; 2010 Sep; 11(10):3705-24. PubMed ID: 21152296
[TBL] [Abstract][Full Text] [Related]
29. Transferable scoring function based on semiempirical quantum mechanical PM6-DH2 method: CDK2 with 15 structurally diverse inhibitors.
Dobeš P; Fanfrlík J; Rezáč J; Otyepka M; Hobza P
J Comput Aided Mol Des; 2011 Mar; 25(3):223-35. PubMed ID: 21286784
[TBL] [Abstract][Full Text] [Related]
30. Insights into the structural basis of 3,5-diaminoindazoles as CDK2 inhibitors: prediction of binding modes and potency by QM-MM interaction, MESP and MD simulation.
Tripathi SK; Singh SK
Mol Biosyst; 2014 Aug; 10(8):2189-201. PubMed ID: 24909777
[TBL] [Abstract][Full Text] [Related]
31. Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.
Řezníčková E; Weitensteiner S; Havlíček L; Jorda R; Gucký T; Berka K; Bazgier V; Zahler S; Kryštof V; Strnad M
Chem Biol Drug Des; 2015 Dec; 86(6):1528-40. PubMed ID: 26198005
[TBL] [Abstract][Full Text] [Related]
32. New scoring functions for virtual screening from molecular dynamics simulations with a quantum-refined force-field (QRFF-MD). Application to cyclin-dependent kinase 2.
Ferrara P; Curioni A; Vangrevelinghe E; Meyer T; Mordasini T; Andreoni W; Acklin P; Jacoby E
J Chem Inf Model; 2006; 46(1):254-63. PubMed ID: 16426061
[TBL] [Abstract][Full Text] [Related]
33. Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy.
Mohammad T; Batra S; Dahiya R; Baig MH; Rather IA; Dong JJ; Hassan I
Molecules; 2019 Dec; 24(24):. PubMed ID: 31847444
[TBL] [Abstract][Full Text] [Related]
34. A flexible-protein molecular docking study of the binding of ruthenium complex compounds to PIM1, GSK-3β, and CDK2/Cyclin A protein kinases.
Liu Y; Agrawal NJ; Radhakrishnan R
J Mol Model; 2013 Jan; 19(1):371-82. PubMed ID: 22926267
[TBL] [Abstract][Full Text] [Related]
35. 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
Vymětalová L; Havlíček L; Šturc A; Skrášková Z; Jorda R; Pospíšil T; Strnad M; Kryštof V
Eur J Med Chem; 2016 Mar; 110():291-301. PubMed ID: 26851505
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors.
Ibrahim DA; El-Metwally AM
Eur J Med Chem; 2010 Mar; 45(3):1158-66. PubMed ID: 20045222
[TBL] [Abstract][Full Text] [Related]
37. Exploring the mechanism of action of spirooxindoles as a class of CDK2 inhibitors: a structure-based computational approach.
Abdjan MI; Shafiq M; Nerukh D; Nur-E-Alam M; Ul-Haq Z
Phys Chem Chem Phys; 2024 Jun; 26(22):16139-16152. PubMed ID: 38787638
[TBL] [Abstract][Full Text] [Related]
38. Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity.
Jorda R; Havlícek L; McNae IW; Walkinshaw MD; Voller J; Sturc A; Navrátilová J; Kuzma M; Mistrík M; Bártek J; Strnad M; Krystof V
J Med Chem; 2011 Apr; 54(8):2980-93. PubMed ID: 21417417
[TBL] [Abstract][Full Text] [Related]
39. Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313.
Talapati SR; Nataraj V; Pothuganti M; Gore S; Ramachandra M; Antony T; More SS; Krishnamurthy NR
Acta Crystallogr F Struct Biol Commun; 2020 Aug; 76(Pt 8):350-356. PubMed ID: 32744246
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and Biological Evaluation of N(2) -Substituted 2,4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and Related 5-Cyano-NNO-azoxy Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors.
Cortese D; Chegaev K; Guglielmo S; Wang LZ; Golding BT; Cano C; Fruttero R
ChemMedChem; 2016 Aug; 11(16):1705-8. PubMed ID: 27355194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
